Citadel Advisors
KALV

Citadel Advisors’s KalVista Pharmaceuticals KALV Stock Holding History

Citadel Advisors’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,000
Closed -$69.2K – 13855
2025
Q1 		$69.2K Sell
6,000
-30,600
-84% -$312K ﹤0.01% 11931
2024
Q4 		$310K Sell
36,600
-61,400
-63% -$636K ﹤0.01% 9587
2024
Q3 		$1.13M Buy
98,000
+88,300
+910% +$1.11M ﹤0.01% 6627
2024
Q2 		$114K Sell
9,700
-20,400
-68% -$238K ﹤0.01% 10723
2024
Q1 		$357K Sell
30,100
-1,100
-4% -$14.7K ﹤0.01% 9100
2023
Q4 		$382K Buy
31,200
+29,700
+1,980% +$270K ﹤0.01% 8662
2023
Q3 		$14.4K Buy
+1,500
New +$15.3K ﹤0.01% 12869
2023
Q1 		– Sell
-13,300
Closed -$89.9K – 15118
2022
Q4 		$89.9K Buy
+13,300
New +$71.2K ﹤0.01% 11363
2021
Q4 		– Sell
-27,900
Closed -$487K – 14313
2021
Q3 		$487K Sell
27,900
-16,900
-38% -$343K ﹤0.01% 9936
2021
Q2 		$1.07M Sell
44,800
-100,800
-69% -$2.64M ﹤0.01% 8193
2021
Q1 		$3.74M Sell
145,600
-35,800
-20% -$941K ﹤0.01% 4925
2020
Q4 		$3.44M Buy
+181,400
New +$3.11M ﹤0.01% 4348

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors's KALV Position: Q1 2026 in Review

Citadel Advisors increased its KalVista Pharmaceuticals (KALV) stake by 159% in Q1 2026, buying an estimated $966K and bringing the position to 97,726 shares worth $1.97M. The position accounts for ﹤0.01% of the portfolio, ranked #6090.

Citadel Advisors first reported a position in KALV in Q2 2015 and has held it in 24 quarters since. The position peaked at $9.6M in Q4 2023. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Citadel Advisors held 97,726 shares of KalVista Pharmaceuticals worth $1.97M as of Q1 2026.
  • Citadel Advisors bought 59,965 KalVista Pharmaceuticals shares in Q1 2026, an estimated $966K.
  • KalVista Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6090 holding.
  • Citadel Advisors first reported a position in KalVista Pharmaceuticals in Q2 2015 and has held it in 24 quarters since.
  • Citadel Advisors's KalVista Pharmaceuticals position peaked at $9.6M in Q4 2023.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.